Peptide-Based Therapeutics: Targeting Amylin, Calcitonin, and Related Receptors
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 296
Special Issue Editors
Interests: GPCR; peptide design; receptor-ligand interaction; obesity
Interests: gastrointestinal tract; cytoprotection; blood vessels; stable gastric pentadecapeptide BPC 157
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Peptide-based drugs had suffered from their relatively short half-life and low bioavailability. Recent pharmaceutical modifications with acylation (or lipidation) have enabled long-acting peptide drugs, for example, with once-weekly injection, to show their clinical efficacy.
This issue will place emphasis on peptide hormone therapeutics targeting amylin, calcitonin, and related peptide hormone receptors. Among other peptide hormones, amylin is a peptide hormone secreted from pancreatic β-cells, and its receptor activation has shown clinical benefits for blood glucose and body weight control. Accordingly, peptide agonists for amylin receptors have been developed and tested for their efficacy for diabetes and obesity. Recent pharmaceutical efforts appear to be focused on obesity drug development targeting amylin receptors.
This Special Issue will collect the pharmaceutical research or review articles reporting how pharmaceutical technology enables long-acting peptide drugs with once-weekly or less injections for clinical efficacy. In addition, preclinical or clinical research using oral formulations of peptide drugs and the related pharmaceutical advances applied to oral administration will be covered with interest.
I hope that many researchers in peptide pharmaceutics towards enhanced pharmacotherapy submit their research and/or review manuscripts to this Special Issue.
Dr. Sangmin Lee
Prof. Dr. Predrag Sikirić
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GPCR
- amylin
- obesity
- diabetes
- peptide-based drugs
- long-acting agonists
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
